Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 18Prostatic Neoplasms 18Sarcoma 5Neoplasms 4Uterine Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer 1Retinoblastoma 1Prostate Cancer With Intermediate Risk 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cholangiocarcinoma 1

Interventions

Radiotherapy 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostate Cancer With Intermediate Risk × Brachytherapy × Clear all
NCT01039038 2011-11-28

CURIEBOOST

Centre Francois Baclesse

Phase 2 Terminated
50 enrolled
Genitourinary

Prostate Cancer With Intermediate Risk

Data powered by HemOnc (CC BY 4.0) Colophon âš¡